Alumis Inc. (ALMS)
Alumis is a South San Francisco drug developer working on TYK2 inhibitor treatments for immune-mediated diseases. It last closed at $4.84 on Nov 17, down 5.84% on the day. The average 12-month price target from 4 analysts is $21.00 (+333.9% from the last close), with a high of $29.00 and a low of $9.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ALMS, 100% of them bullish and 0% bearish. In the past 30 days there were 4 dark pool prints totaling $997K, the largest $315K.
Key Stats
Last 12 monthsNot reported for this period.
From ALMS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on ALMS in the past 90 days. The average target is $21.00, with a high of $29.00 and a low of $9.00, compared with the last close of $4.84.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Oppenheimer | Target lowered | Buy | $37 → $28 |
| Nov 13 | Wells Fargo | Target lowered | Buy | $25 → $18 |
| Nov 13 | HC Wainwright & Co. | Target lowered | Buy | $15 → $9 |
| Sep 2 | Oppenheimer | Maintained | Buy | $37 |
| Sep 2 | Wells Fargo | Maintained | Buy | $25 |
Technical Analysis
The stock is 31% below its 20 day and 45% below its 50 day average. It is 318% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $4.70, and the nearest resistance the Pivot at $4.89.
| RSI (14) | 28.66 | Oversold below 30 | Oversold |
| MACD | -0.67 | Below its signal line | Bearish |
| Stochastic | 5.4 | Near the bottom of its range | Oversold |
| ADX (14) | 41.4 | Strong downtrend | |
| Williams %R | -94.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -250.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −25.5% | Change over 10 sessions | Bearish |
| ATR (14) | $0.52 | Typical daily range, 10.8% of price |
| RSI (14) | 23.29 | Oversold below 30 | Oversold |
| MACD | -4.61 | Below its signal line | Bearish |
| Stochastic | 0.8 | Near the bottom of its range | Oversold |
| ADX (14) | 38.9 | Trending down | |
| Williams %R | -99.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -73.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −47.3% | Change over 10 sessions | Bearish |
| ATR (14) | $2.46 | Typical daily range, 50.8% of price |
What happened before
See how ALMS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in ALMS in the last 90 days.
Dark Pool
30DALMS Institutional Ownership
Full report →- ▲125 buying vs 92 selling
- ▼Shares held by funds -5.0%
- ▲Funds holding +2
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 200 | 198 | +1.0% |
| In funds' top 10 | 8 | 18 | −55.6% |
| Held by funds | – | – | – |
| New / increased | 45 / 80 | 27 / 74 | +23.8% |
| Reduced / sold out | 50 / 42 | 61 / 24 | +8.2% |
| Put/call ratio | 0.05 | 0.02 | +233.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALMS is in one of them and how their past ALMS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALMS in an article yet. Here's the latest on the wider market.
About Alumis
Alumis is a drug developer based in South San Francisco, California, that is working on treatments for immune-mediated diseases. Its lead candidate, envudeucitinib, is in Phase 3 testing for plaque psoriasis and is also being studied in lupus. The company is developing a second TYK2 inhibitor for neuroinflammatory conditions and holds an antibody being evaluated for thyroid eye disease. Its target patients are people living with immune-mediated diseases such as psoriasis and lupus.
- Headquarters
- South San Francisco, CA


